Wealth Enhancement Advisory Services LLC Grows Stock Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Wealth Enhancement Advisory Services LLC lifted its position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 44.3% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 67,893 shares of the company’s stock after buying an additional 20,848 shares during the period. Wealth Enhancement Advisory Services LLC owned approximately 0.10% of Zentalis Pharmaceuticals worth $250,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of ZNTL. ProShare Advisors LLC raised its holdings in shares of Zentalis Pharmaceuticals by 9.0% during the 1st quarter. ProShare Advisors LLC now owns 15,436 shares of the company’s stock valued at $243,000 after buying an additional 1,274 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Zentalis Pharmaceuticals by 20.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock valued at $54,999,000 after buying an additional 585,644 shares during the period. Kennedy Capital Management LLC bought a new stake in shares of Zentalis Pharmaceuticals in the 1st quarter worth $189,000. Opaleye Management Inc. bought a new stake in shares of Zentalis Pharmaceuticals in the 1st quarter worth approximately $3,152,000. Finally, SG Americas Securities LLC acquired a new position in shares of Zentalis Pharmaceuticals in the 2nd quarter worth $58,000.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on ZNTL shares. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Zentalis Pharmaceuticals in a research note on Monday, August 12th. Oppenheimer reaffirmed an “outperform” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a report on Monday, September 16th. Finally, Wedbush upgraded shares of Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price objective on the stock in a report on Monday, August 12th. Five analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Zentalis Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $10.25.

Zentalis Pharmaceuticals Price Performance

ZNTL opened at $4.03 on Tuesday. The firm’s fifty day moving average price is $3.38 and its two-hundred day moving average price is $5.59. The company has a market capitalization of $286.57 million, a price-to-earnings ratio of -1.48 and a beta of 1.74. Zentalis Pharmaceuticals, Inc. has a 1 year low of $2.66 and a 1 year high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Friday, August 9th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.84) by ($0.40). During the same period last year, the company earned ($1.85) EPS. As a group, equities analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -3.02 EPS for the current year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.